RVG 116648 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000469-33-NL
(EUCTR)
12/10/202125/03/2021Scientific medical research comparing the effectiveness of Infliximab by injection in the abdominal tissiue (subcutaneous) monotherapy and infliximab subcutaneous injection with anti-inflammatory drugs in the treatment of moderate to severe chronic inflammatory bowel disease.A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn’s Disease. - DIRECT CD Crohns disease;Therapeutic area: Body processes [G] - Biological Phenomena [G16]Trade Name: Remsima
Product Name: Remsima
Product Code: EMEA/H/C/002576
Trade Name: Puri Nethol
Product Name: Puri Nethol
Product Code: RVG00859
Trade Name: Imuran
Product Name: Imuran
Trade Name: Thiosix
Product Name: Thiosix
Product Code: RVG 114681
Trade Name: Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml
Product Name: Ebetrex
Product Code: RVG 116648
Amsterdam UMC location AMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
158Phase 3;Phase 4Netherlands